New
SM
Clara Fargo
EBMT Clinical Research Quality Assurance Coordinator
I have finalised the demo for the ICH-GCP E6 R3 refresher course. Overall, I liked the content and the interface. I also want to thank Whitehall Train...
Contamination Control Strategy (CCS) Course & Certification
Intermediate
Watch Preview
4.7
★★★★★
97% Recommended
3 hours
198 active users
3 points
Watch Preview
Your Study Basket
Contamination Control Strategy (CCS)
| Total | |
🎁 FREE Bonus Included
eBookWorth £29— Yours FREE when you purchase today.
VAT is levied as per your country’s applicable rules and rates at checkout
Save more with a monthly or annual plan that includes this course
Secure Payment Service
Rest assured we use secure processes to protect your payment.
Secured by:
About
Contamination Control Strategy (CCS) training provides comprehensive knowledge of developing, implementing, and maintaining an effective contamination control program across pharmaceutical manufacturing processes. The course covers contamination sources, risk assessment, cleanroom contamination control, facility and equipment design, environmental monitoring, personnel practices, cleaning and disinfection, sterilization, aseptic processing, and quality risk management in line with current regulatory expectations.
This Contamination Control Strategy (CCS) Training Course & Certification provides practical understanding of EU GMP Annex 1 requirements, contamination risk management principles, CCS documentation, validation, environmental monitoring programs, deviation investigations, CAPA, and continuous improvement practices to ensure product quality, patient safety, and regulatory compliance.
Who Should Enrol?
- Quality Assurance (QA) Professionals
- Quality Control (QC) Professionals
- Microbiology and Environmental Monitoring Personnel
- Aseptic Manufacturing and Production Professionals
- Validation and Qualification Engineers
- Sterility Assurance Specialists
- Regulatory Affairs and Compliance Professionals
- Anyone involved in contamination prevention, sterile manufacturing, and pharmaceutical quality systems
What you will learn
Understand the principles of Contamination Control Strategy (CCS), including contamination sources, contamination pathways, and holistic risk-based approaches in pharmaceutical manufacturing.
Learn global regulatory expectations, including EU GMP Annex 1, PIC/S guidance, ICH quality guidelines, and industry best practices for contamination prevention.
Gain knowledge of cleanroom design, environmental monitoring, personnel qualification, aseptic processing, cleaning and disinfection, and contamination risk management.
Understand CCS implementation, documentation, validation, continuous monitoring, deviation management, CAPA, and lifecycle maintenance to ensure ongoing compliance and product quality.
Course Syllabus
- The Annex 1 mandate for a documented, holistic, site-wide CCS
- A true CCS versus a list or a binder - sources to controls to monitoring to effectiveness
- The CCS within the pharmaceutical quality system (ICH Q10)
- The regulatory landscape: EU/EEA, PIC/S and WHO alignment versus the US framework
- Microbial, particulate and endotoxin dimensions of contamination
- Sterivance: the site, the Immunovel line and the first holistic CCS
- Quality risk management (ICH Q9(R1)) as the engine of the CCS
- Identifying microbial, particulate and endotoxin sources and routes
- Selecting and running appropriate risk tools (FMEA, risk matrices, HACCP-style)
- Formality and avoidance of subjectivity in QRM
- Justifying controls and their extent on a risk basis; residual risk and no zero risk
- Sterivance: a QRM workshop on the filling line
- The Annex 1 CCS element set (paraphrased from §2.5)
- Mapping each element to sources, controls and monitoring
- Building the element-to-control linkage - the golden thread
- Signposting technical detail to the EU GMP Annex 1 course
- Using the mapping matrix as a working document
- Sterivance: mapping the elements to controls and monitoring
- Structuring and authoring the CCS (site versus process level)
- Ownership, approval, version control and governance
- Writing the linkage from risk to control to monitoring to effectiveness
- Referencing supporting registers and assessments rather than duplicating them
- Keeping the document a strategy, not an inventory
- Sterivance: writing the CCS document and its golden thread
- The hierarchy of controls: engineering/technical, procedural, organisational
- Justifying barrier and separation choices within the CCS
- Analysing control interactions and combined effect
- Residual risk after controls and its management
- Preferring higher-tier controls and evidencing reliance on procedural ones
- Sterivance: justifying the barrier choice in the CCS
- Defining how the CCS assesses control effectiveness
- Environmental monitoring, APS/media fills and trending as effectiveness evidence
- Leading and lagging indicators
- Aggregating signals to judge the combined strategy
- Responding when the strategy is not effective
- Sterivance: an EM trend and a media-fill signal reveal an underperforming control
- Periodic and triggered review to keep the CCS live
- Integrating change control, CAPA and management review
- Linking the CCS to PQR/APQR, knowledge management and continual improvement
- Version control and the change log
- Feeding contamination events and excursions back into the strategy
- Sterivance: a living-document update via change control and management review
- How inspectors assess a CCS
- The common pitfalls: static binder, list without linkage, no effectiveness assessment, not maintained
- Performing a CCS gap assessment against the Annex 1 element set
- Defending the strategy and its residual-risk decisions
- Recognising when QP, microbiological SME or competent-authority input is required
- Sterivance: a mock inspection exposes a list-without-linkage gap that is remediated
- The eight discipline rules, revisited
- The CCS golden thread in one page
- The ten templates and how to deploy them
- Common CCS failures and how to avoid them
- What this course does not certify - the CCS-integrity disclaimer, restated
- 📘 Bonus:Contamination Control Strategy (CCS) eBook (Free with purchase)
Course Benefits
Free eBook
Get our exclusive eBook with every purchase - a complete companion guide to the course, yours to keep forever
CPD Points
Gain Continuing Professional Development (CPD) Points, accredited by The Faculty of Pharmaceutical Medicine of the Royal College of Physicians of the United Kingdom. These can be used to count towards the distance learning element of any scheme that comes under the umbrella of The Academy of Medical Royal Colleges or any other scheme for which there is mutual recognition.
Certification
Receive a personal certificate to show your subject knowledge on course completion.
Affordable
You get excellent value through our cost-effective prices. We can also offer you group discounts on larger purchases.
Flexibility
The course saves you time through the convenience of online availability. This lets you complete the interactive course at your own comfort.
Keep Up to Date
You will stay up to date with the contamination-control framework and its status across jurisdictions: EU GMP Annex 1 (2022), operational from 25 August 2023 with the §8.123 lyophiliser-loading provision effective 25 August 2024; the PIC/S-aligned Annex 1 (PE 009) and WHO's aligned sterile-GMP text; EudraLex Volume 4 Chapters 1 and 5; ICH Q9(R1) Quality Risk Management and ICH Q10 Pharmaceutical Quality System; ISO 14644; and, for contrast, the US framework (21 CFR 211 and FDA's 2004 aseptic-processing guidance), which does not mandate an "Annex 1 CCS" by that name - as our training courses are constantly monitored, reviewed and updated. Guidance is distinguished from law and from standards; drafts and transition dates are flagged; positions were verified in July 2026 and must be re-verified against the source for the relevant jurisdiction before use.
Learn from Industry Experts
The course content is Whitehall Training editorial material, developed to reflect established sterile-manufacturing and contamination-control practice - how a holistic CCS is actually authored, linked, evidenced and maintained, and the failure modes that appear when it becomes a static binder, a list without linkage, or a strategy whose effectiveness is assumed rather than assessed. It is built around a single fictional case study, Sterivance Biologics and its aseptic fill-finish of the biologic Immunovel, so that every authoring, mapping, control-hierarchy, effectiveness and maintenance decision is one the learner can reason through. Regulations, guidance and standards are paraphrased and section-referenced; they are never reproduced, and nothing in the course is legal advice or a regulator endorsement. It complements, and does not replace, Whitehall's EU GMP Annex 1 technical course.
Our Certified Customers
Learner Rating & Reviews
4.7
★★★★★★
Average Rating
536 global ratings
★★★★★
87.0%
★★★★★
5.0%
★★★★★
3.0%
★★★★★
3.0%
★★★★★
2.0%
